© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
Siltuximab is now approved for multicentric Castleman’s disease > >
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.